The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Fiorcari, Stefania ^a,d   Brown, Wells S ^a   McIntyre, Bradley W ^a   Estrov, Zeev ^a   Maffei, Rossana ^d   O'Brien, Susan ^a   Sivina, Mariela ^a   Hoellenriegel, Julia ^a   Wierda, William G ^a   Keating, Michael J ^a   Ding, Wei ^b   Kay, Neil E ^b   Lannutti, Brian J ^c   Marasca, Roberto ^d   Burger, Jan A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c GILEAD SCIENCES INC   (United States)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; IDELALISIB; INTEGRIN; PHOSPHATIDYLINOSITOL 3 KINASE; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CELL ADHESION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECTS; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL LINE;

ANIMALS; BONE MARROW CELLS; CELL ADHESION; CELL LINE, TUMOR; CELL SURVIVAL; ENDOTHELIAL CELLS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; INTEGRIN ALPHA4BETA1; INTEGRINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PURINES; QUINAZOLINONES; SIGNAL TRANSDUCTION; STROMAL CELLS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84893472705     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083830     Document Type: Article

References (40)

1. Chiorazzi N, Hatzi K, Albesiano E (2005) B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens. Ann N Y Acad Sci 1062: 1-12. doi:10.1196/annals.1358.002. PubMed: 16461783.
2. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114: 3367-3375. doi:10.1182/blood-2009-06-225326. PubMed: 19636060.
3. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M et al. (2000) Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96: 2655-2663. PubMed: 11023495.
4. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV (1996) Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 92: 97-103. doi:10.1046/j.1365-2141.1996.00305.x. PubMed: 8562418. (Pubitemid 26018774)
5. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P (1998) Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91: 2387-2396. PubMed: 9516138.
6. Maffei R, Martinelli S, Castelli I, Santachiara R, Zucchini P et al. (2010) Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leuk Res 34: 312-321. doi:10.1016/j.leukres.2009.06.023. PubMed: 19616847.
7. Buggins AG, Pepper C, Patten PE, Hewamana S, Gohil S et al. (2010) Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res 70: 7523-7533. PubMed: 20736369.
8. Stein H, Bonk A, Tolksdorf G, Lennert K, Rodt H et al. (1980) Immunohistologic analysis of the organization of normal lymphoid tissue and non-Hodgkin's lymphomas. J Histochem Cytochem 28: 746-760. doi:10.1177/28.8. 7003001. PubMed: 7003001.
9. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P et al. (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115: 755-764. doi:10.1172/JCI200523409. PubMed: 15711642. (Pubitemid 40322252)
10. Burger JA (2011) Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011: 96-103.
11. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM et al. (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115: 2578-2585. doi:10.1182/blood-2009-08-236471. PubMed: 19965662.
12. O'Brien S, Burger JA, Blum KA, Furman RR, Coutre SE et al. (2011) The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. ASH Annual Meeting. Abstracts 118: 983-.
13. Furman RR, Byrd JC, Brown JR, Coutre SE, Benson DM Jr. et al. (2010) CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood 116: 31a.
14. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B et al. (2011) CAL-101, a p110{delta} selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117: 591-594. doi:10.1182/blood-2010-03-275305. PubMed: 20959606.
15. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X et al. (2011) Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood.
16. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H et al. (2011) The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118: 3603-3612. doi:10.1182/blood-2011-05-352492. PubMed: 21803855.
17. Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N et al. (2010) PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 116: 1460-1468. doi:10.1182/blood-2009-06-222943. PubMed: 20505158.
18. Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V et al. (2012) PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119: 1897-1900. doi: 10.1182/blood-2011-10-386763. PubMed: 22210877.
19. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W et al. (2010) Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116: 2078-2088. doi:10.1182/blood-2010-02-271171. PubMed: 20522708.
20. Springer TA (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76: 301-314. doi:10.1016/0092-8674(94)90337-9. PubMed: 7507411.
21. Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA et al. (1998) Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 279: 381-384. doi:10.1126/science.279.5349.381. PubMed: 9430588. (Pubitemid 28063373)
22. Rose DM, Han J, Ginsberg MH (2002) Alpha4 integrins and the immune response. Immunol Rev 186: 118-124. doi:10.1034/j.1600-065X.2002.18611.x. PubMed: 12234367.
23. Gattei V, Bulian P, Del Principe MI, Zucchetto A, Maurillo L et al. (2008) Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 111: 865-873. doi:10.1182/blood-2007-05-092486. PubMed: 17959854.
24. Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE et al. (2008) CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol 140: 537-546. doi:10.1111/j.1365-2141.2007.06965.x. PubMed: 18275431. (Pubitemid 351230080)
25. Brachtl G, Sahakyan K, Denk U, Girbl T, Alinger B et al. (2011) Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells. PLOS ONE 6: e23758. doi:10.1371/journal. pone.0023758. PubMed: 21876768.
26. Butcher EC, Picker LJ (1996) Lymphocyte homing and homeostasis. Science 272: 60-66. doi:10.1126/science.272.5258.60. PubMed: 8600538. (Pubitemid 26110755)
27. Mueller SN, Germain RN (2009) Stromal cell contributions to the homeostasis and functionality of the immune system. Nat Rev Immunol 9: 618-629. PubMed: 19644499.
28. Kawano Y, Kobune M, Yamaguchi M, Nakamura K, Ito Y et al. (2003) Ex vivo expansion of human umbilical cord hematopoietic progenitor cells using a coculture system with human telomerase catalytic subunit (hTERT)-transfected human stromal cells. Blood 101: 532-540. doi:10.1182/blood-2002-04-1268. PubMed: 12393449. (Pubitemid 36077574)
29. Kay NE, Shanafelt TD, Strege AK, Lee YK, Bone ND et al. (2007) Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leuk Res 31: 899-906. doi:10.1016/j.leukres.2006. 11.024. PubMed: 17241660. (Pubitemid 46856727)
30. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S et al. (1990) VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60: 577-584. doi:10.1016/0092-8674(90)90661-W. PubMed: 1689216.
31. Burger JA, Burger M, Kipps TJ (1999) Chronic Lymphocytic Leukemia B Cells Express Functional CXCR4 Chemokine Receptors That Mediate Spontaneous Migration Beneath Bone Marrow Stromal Cells. Blood 94: 3658-3667. PubMed: 10572077.
32. Bednarczyk JL, Szabo MC, Wygant JN, Lazarovits AI, McIntyre BW (1994) Identification of a combinatorial epitope expressed by the integrin alpha 4 beta 1 heterodimer involved in the regulation of cell adhesion. J Biol Chem 269: 8348-8354. PubMed: 7510686. (Pubitemid 24200252)
33. Freeman SA, Lei V, Dang-Lawson M, Mizuno K, Roskelley CD et al. (2011) Cofilin-mediated F-actin severing is regulated by the Rap GTPase and controls the cytoskeletal dynamics that drive lymphocyte spreading and BCR microcluster formation. J Immunol 187: 5887-5900. doi:10.4049/jimmunol.1102233. PubMed: 22068232.
34. Swerlick RA, Lee KH, Li LJ, Sepp NT, Caughman SW et al. (1992) Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells. J Immunol 149: 698-705. PubMed: 1378077.
35. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S et al. (1989) Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 59: 1203-1211. doi:10.1016/0092-8674(89)90775-7. PubMed: 2688898. (Pubitemid 20024630)
36. Spaargaren M, Beuling EA, Rurup ML, Meijer HP, Klok MD et al. (2003) The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med 198: 1539-1550. doi:10.1084/jem.20011866. PubMed: 14610042. (Pubitemid 37467168)
37. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V et al. (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119: 1182-1189. doi:10.1182/blood-2011-10-386417. PubMed: 22180443.
38. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, et al. (2009) B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 114: 1029-1037.
39. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ (2001) Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest 107: 305-315. doi:10.1172/JCI11092. PubMed: 11160154. (Pubitemid 32157962)
40. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY et al. (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119: 2590-2594. doi:10.1182/blood-2011-11-390989. PubMed: 22279054.